Zogenix pushes its Series B to $71M

San Diego-based Zogenix has piled an additional $20 million on its Series B, bringing its total for the round to a whopping $71 million as it builds up a cache of cash for a planned launch of its needle-free delivery system. Chicago Growth Partners proffered the cash, joining Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Abingworth Management and new investor Oxford Finance Corporation in the second round.

"Zogenix has developed an innovative product by incorporating a needle-free delivery system, which potentially could also be used for a variety of pharmaceuticals," said Chicago Growth Partner's  Dr. Arda Minocherhomjee, who is joining the board. "The company has a strong management team and board, and is well positioned to capture share in select market segments."

As we reported in September, Zogenix plans to launch Sumavel DosePro, a needle-free delivery system which was recently approved by the FDA to treat migraines, in January. Co-promoter Astellas pharma will also be involved in the roll-out. Most of the money raised in this round will support the production of inventory and building the Zogenix commercial organization of over 105 people.

- check out Zogenix's release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.